Enterome to present updates on EO2401, its first-in-class OncoMimics™ therapeutic cancer vaccine targeting solid tumors, at ESMO Congress 2022
Read more
18
July 2022
Enterome signs major strategic R&D collaboration with Nestlé Health Science to develop and commercialize new AllerMimics™ and EndoMimics™ immunotherapies for food allergies and inflammatory bowel disease
Read more
06
June 2022
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for glioblastoma, at ASCO 2022
Read more
06
June 2022
Enterome presents proof-of-concept immune response data and first clinical data from Phase 1/2 trial with EO2401, a first-in-class OncoMimics™ therapeutic cancer vaccine for adrenocortical carcinoma, at ASCO 2022
Read more
27
May 2022
Enterome to present three abstracts on its novel OncoMimics™ cancer immunotherapies at ASCO 2022
Read more
23
May 2022
Enterome to present promising clinical progress on its OncoMimics™ pipeline and Mimicry Platform at Jefferies Healthcare Conference
Read more
19
May 2022
Enterome to present world first clinical data with EO2401, its first-in-class off-the-shelf OncoMimics™ therapeutic cancer vaccine, at ASCO 2022
Read more
05
April 2022
Enterome to present the significant potential of its Mimicry concept, platform and pipeline at BMO’s Biopharma Spotlight Series conference – Immunology and Inflammation
Read more
10
November 2021
Enterome to present significant progress with its OncoMimics™ pipeline at Jefferies London Healthcare Conference
